

Review

Neurosteroids and premenstrual dysphoric disorder

Marie Bixo, Louise Stiernman and Torbjörn Bäckström

Background

Premenstrual dysphoric disorder (PMDD) is common, with at least 3% of the female population affected by one or more of the typical mood symptoms of depression, irritability, mood swings and anxiety. The cyclicity and close relationship to the luteal phase of the menstrual cycle is characteristic for this syndrome and positive allosteric modulators (PAMs) on the GABA_A receptor, especially allopregnanolone, are believed to be involved in the symptomatology.

Aim

To summarise the research on the role of PAMs and other neuroactive steroids in the pathophysiology of PMDD.

Method

PubMed was searched for articles including the terms Premenstrual syndrome, AND neurosteroids OR allopregnanolone OR GABA OR oestradiol. Many additional publications were previously known to the authors and basic animal research was covered in a secondary step through reference lists.

Results

There is evidence that allopregnanolone, like other PAMs of the GABA_A receptor, is sedative in high concentrations and, in a minor proportion of the population, causes anxiety and irritability at lower levels, pointing to an inter-individual difference in sensitivity. In research comparing women with PMDD and healthy controls, differences in brain function and subcomposition of GABA_A

receptors related to levels of allopregnanolone have been found. Also, the varying levels of neuroactive steroids in general seem to worsen the symptoms. Suppressed ovulation is effective but add-back hormones are necessary to prevent severe side-effects and could cause adverse mood in these individuals.

Conclusions

There is yet no effective treatment for PMDD available. Allopregnanolone seems to be a key provocateur of PMDD symptoms in susceptible individuals. Future research should focus on interventions that interfere with the effects of neurosteroids or the plasticity of the GABA_A receptor itself.

Keywords

Neurosteroids; allopregnanolone; γ -amino-butyric acid (GABA); premenstrual dysphoric disorder.

Copyright and usage

© The Author(s), 2025. Published by Cambridge University Press on behalf of Royal College of Psychiatrists. This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike licence (<https://creativecommons.org/licenses/by-nc-sa/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the same Creative Commons licence is used to distribute the re-used or adapted article and the original article is properly cited. The written permission of Cambridge University Press must be obtained prior to any commercial use.

Premenstrual dysphoric disorder (PMDD) is typified by mood symptoms, including irritability, depressed mood, anxiety and emotional lability, that consistently recur in the premenstrual phase of the menstrual cycle and seriously impact quality of life.^{1,2} The pooled prevalence in mixed samples has been estimated at 3.2% in a recently published meta-analysis,³ but around 12% of women require medical management for premenstrual symptoms.² Although mood symptoms decline or disappear after the start of each menstruation, the disease burden is severe⁴ and, in some cases, PMDD is associated with suicidality.⁵ The strict DSM-5 criteria for PMDD state that five or more different mental and somatic symptoms, including at least one of the core symptoms depressed mood, anxiety, irritability and mood swings, need to be present in the premenstrual period and become minimal or absent during the postmenstrual week.⁶ Furthermore, the symptoms should incur significant distress and/or have a significant impact on relationships, social functioning and work or student performance. There is wide variety in how the symptoms manifest in terms of type of dominating symptom and duration during the luteal phase, but the intra-individual pattern is usually stable over time.⁷ Of the core symptoms, irritability and anxiety are more common than depression and mood swings,⁸ and irritability is, not surprisingly, strongly associated with impairment of relationships.^{7,9}

A PMDD diagnosis should be based on at least 2 months of prospective daily ratings of symptoms on a validated instrument and not be an exacerbation of an underlying condition (e.g. major depression or an anxiety disorder).⁶ Although PMDD is not

considered an entirely psychiatric condition (despite the shared symptomatology and inclusion in DSM-5), comorbidity with psychiatric disorders is common¹⁰ and earlier trauma seems to be a significant risk factor for PMDD later in life.^{11,12}

Menstrual cycle-linked symptom pattern in PMDD

A normal menstrual cycle is characterised by pronounced fluctuations in circulating levels of ovarian steroids. The pathophysiology of PMDD is unclear, but a temporal association with circulating progesterone and its metabolite allopregnanolone during the premenstrual phase has been established¹³ (Fig. 1). However, none of these steroids are useful as a biomarker for PMDD, because peripheral luteal phase levels in PMDD are not different from those in asymptomatic individuals.¹⁴ Instead, the prevailing hypothesis today is that individuals with PMDD are vulnerable to hormonal fluctuations.¹³ A prerequisite for PMDD symptoms is that a corpus luteum develops during menstrual cycles. This is evidenced by studies showing that PMDD symptoms are abolished in spontaneously anovulatory cycles, as well as during induced anovulation by gonadotropin-releasing hormone (GnRH) analogues.^{15,16} However, in anovulatory women previously diagnosed with PMDD, recurrence of typical symptoms can be triggered by a combination of continuous oestradiol and native progesterone, or by a synthetic progestin in a cyclical regimen mimicking a physiological menstrual cycle




Fig. 1 (a) Hormonal changes during a normal, idealised menstrual cycle. The figure gives an overview of the fluctuations without displaying exact peripheral levels. Adapted from Draper et al.¹²⁹ and Bäckström et al.¹³ (b) Mean prospective scorings of the core symptoms irritability and depression in 38 menstrual cycles in 19 women with premenstrual dysphoric disorder (an idealised menstrual cycle corresponding to the allopregnanolone fluctuations displayed in the top panel). Adapted from Bäckström et al.¹³

pattern.^{17,18} This further strengthens the hypothesis of an underlying individual susceptibility.

Why then, are some women extremely sensitive to hormonal fluctuations during the luteal phase? In women with PMDD, serum levels of progesterone are closely linked to adverse mood (with a slight delay in peak symptoms). Progesterone has several target receptors in the brain. Genomic progesterone receptors, PR-A and PR-B are involved in reproductive function but are also expressed in areas associated with cognition and emotional processing.¹⁴ Furthermore, a number of different membrane progesterone receptors and membrane binding sites (PGRMC) are known from animal research.¹⁹ However, studies trialling drugs that directly antagonise progesterone receptors, e.g. mifepristone, have failed to show positive effects on mood, at least when given after ovulation has occurred.²⁰ Instead, decades of research have highlighted the role of progesterone-derived neurosteroids as important modulators of mood and behaviour.

The concept of neuroactive steroids is limited to steroids with specific targets in the central nervous system, while neurosteroids are defined as steroids that can be synthesised within the brain, *de novo*, from cholesterol or other precursors. The most well-known neurosteroids are allosteric modulators of the γ -amino-butyric acid (GABA)_A receptor or the NMDA (N-methyl-D-aspartate) receptor. One of the most potent is allopregnanolone, which acts as a positive allosteric modulator of the GABA_A receptor. PMDD symptoms arise in the context of allopregnanolone fluctuations (see Fig. 1). It is well documented that some individuals react paradoxically to sedatives such as benzodiazepines, barbiturates, alcohol and allopregnanolone, which are all active on the GABA_A receptor, and thus experience anxiogenic rather than anxiolytic effects. In these cases the effect is bimodal: in high concentrations/dosages it is anxiolytic, sedative/anaesthetic and anti-epileptic,^{21–23} but in low concentrations/dosages it is anxiogenic and promotes aggression.^{24–31} The




Fig. 2 Schematic biosynthesis pathways of neuroactive steroids. Bold arrows indicate the key pathways relevant for the pathophysiology of premenstrual dysphoric disorder. Blue boxes, positive GABA modulators; oval boxes, negative GABA modulators; dotted boxes, intermediary steroids. The most important enzymatic steps are depicted as a, 5 α -reductase; b, 5 β -reductase; c, 3 α -hydroxysteroid dehydrogenase; d, 3 β -hydroxysteroid dehydrogenase; e, sulphatase; and f, aromatase. GABA, γ -amino-butyric acid; PAM, positive allosteric modulator; NAM, negative allosteric modulator; GAMSA, GABA_A receptor-modulating steroid antagonist; DHP, dihydroprogesterone; THDOC, tetrahydrodeoxycorticosterone; NMDA, N-methyl-D-aspartate.

occurrence of these paradoxical reactions to GABA_A agonists in the general population is 3% for severe irritability and aggression and up to 20% for moderate mood deterioration in specific patient groups,^{32–34} prevalence figures similar to those for PMDD.^{3,35} The bimodal, paradoxical response to allopregnanolone has been shown in both animal and human studies.^{24,25,36} In a study using oestrogen/progesterone cyclical treatment in postmenopausal women, negative mood symptoms were induced related to low luteal phase allopregnanolone concentrations, but decreased when higher concentrations were reached.³⁶ A functional magnetic resonance imaging (fMRI) study showed that luteal phase levels of progesterone/allopregnanolone induced paradoxically higher amygdala activation in response to an emotion-processing task.³⁷ High concentrations of allopregnanolone, on the other hand, are associated with reduced amygdala responses, reflecting the effects on the brain of benzodiazepines given in anxiolytic doses.³⁸

Positive allosteric modulators of the GABA_A receptor

Allopregnanolone (3 α -OH-5 α -pregnan-20-one) is an endogenous progesterone metabolite and a potent positive allosteric modulator (PAM) of the GABA_A receptor, enhancing GABAergic activity.³⁹ The GABA system is the main inhibitory transmitter system in the brain, and the GABA_A receptor is a membrane-bound chloride channel consisting of five subunits. At least 19 different subunits have been identified to date, making possible numerous combinations.⁴⁰ GABA_A receptors are ubiquitously distributed within the brain and are located both in synapses (mediating phasic inhibition) and extrasynaptically (mediating tonic inhibition).⁴¹ GABA_A receptor subunit composition varies in a site-specific manner throughout the brain,⁴² and the precise composition of the receptor determines its pharmacodynamic response to GABA_A-active drugs.^{40,43,44} Allopregnanolone is produced from progesterone by a two-step enzymatic conversion involving the enzymes

5 α -reductase type I and 3 α -hydroxysteroid dehydrogenase (Fig. 2). These two enzymes are expressed in the brain and colocalised in, for example, specific neurons in the cerebral cortex, hippocampus and amygdala.⁴⁵ In a human post-mortem study, levels of allopregnanolone in peripheral blood were reflected in the brain but also accumulated in specific areas, e.g. amygdala.⁴⁶ Peripheral levels of allopregnanolone mirror those of progesterone during the menstrual cycle and in pregnancy,¹³ but allopregnanolone is also secreted from the adrenal cortex as a reaction to stress.⁴⁷

Allopregnanolone acts as a PAM of the GABA_A receptor in the lower nanomolar concentration range, but higher concentrations can activate the receptor directly without the presence of GABA.⁴⁸ Extrasynaptic receptors containing a delta subunit are known to be acutely sensitive to allopregnanolone, and some researchers have argued that delta-containing GABA_A receptors are allopregnanolone's main target at physiological concentration ranges.⁴⁹ Like other PAMs of the GABA_A receptor and pharmaceutical compounds such as benzodiazepines and barbiturates, allopregnanolone has sedative, anaesthetic and anti-epileptic effects in both animals and humans at high concentrations.^{50–53} In addition, it has been shown to mediate anxiolytic effects in animal experiments.⁵⁴ One of several possible physiological roles of endogenous allopregnanolone is as a neuroprotective agent, and it contributes to the normal development of the foetal brain during pregnancy.^{55,56} During the past 20 years, allopregnanolone research has expanded rapidly in several areas, mostly related to mood disorders.⁵⁷ As a potential pharmaceutical, allopregnanolone is especially appealing since it is an endogenous steroid with a positive safety profile.⁵⁸ Allopregnanolone is approved by the American Food and Drug Administration for treatment of postpartum depression under the names Brexanolone (intravenous administration) and Zuranolone (oral administration).^{58,59} Other PAMs of the GABA_A receptor include pregnanolone (an isomer of allopregnanolone), androsterone (3 α -OH-5 α -androstane-17-one, a metabolite of testosterone), and 5 α -tetrahydrodeoxycorticosterone (a metabolite of corticosterone)^{39,60,61} (see Fig. 2). Today,

allopregnanolone is by far the most dominant and interesting PAM in the expanding research field of neurosteroids.⁵⁷

GABA_A receptor-modulating steroid antagonists and negative allosteric modulators of the GABA_A receptor

Isoallopregnanolone (3 β -OH-5 α -pregnan-20-one) is a GABA_A receptor-modulating steroid antagonist (GAMSA) that inhibits the effect of allopregnanolone. Its antagonising effect has been shown both in vitro and in animal experiments.^{62–64} As a metabolite of progesterone and an isomer to allopregnanolone, serum levels of endogenous isoallopregnanolone fluctuate similarly during different reproductive states.^{65–67} During pregnancy, levels of isoallopregnanolone increase in parallel with allopregnanolone at a constant ratio of approximately 1:4 in peripheral blood, and during the menstrual cycle the ratio is between 1:4 and 1:2.⁶⁸ Isoallopregnanolone can be produced from allopregnanolone by either a two-step enzymatic reaction (with dihydropregesterone produced as an intermediate) or direct epimerisation^{69,70} (see Fig. 2). The enzymes responsible for these conversions are present within the brain, but are most abundant in the liver. The physiological role of isoallopregnanolone is at present unknown; in early studies of neuroactive steroids, the compound was even used as an inert control.⁷¹ Isoallopregnanolone has no effects of its own on the GABA_A receptor in vitro.⁷² The effect of GAMSA on GABA_A receptor function seems to be specific to neuroactive steroids such as allopregnanolone, because it does not influence the action of other GABA_A receptor agonists such as benzodiazepines or barbiturates, or GABA itself.^{62,73}

Pregnenolone sulphate is a negative allosteric modulator (NAM) of the GABA_A receptor, but it is also a GAMSA because it inhibits the effects of allopregnanolone on GABAergic transmission and a PAM of the NMDA receptor (Fig. 2). The effect of GAMSA has been shown in vitro in rat neurons using patch-clamp technique⁷⁴ and, more recently, more direct inhibitory actions of pregnenolone sulphate on the GABA_A receptor have been shown.⁷⁵

Experimental effects of PAMs, GAMSA and NAMs in humans*

Measurement of saccadic eye velocity (SEV) is used to quantify GABA_A receptor sensitivity⁷⁶ and, in studies of healthy women in the follicular phase, intravenous allopregnanolone dose-dependently increased subjective sedation and decreased maximal SEV.⁵⁰ However, when isoallopregnanolone was added, the effect on SEV was inhibited.⁷⁷

Studies using fMRI have shown that exogenous administration of PAMs influences the patterns of activity in brain networks that are highly relevant to the pathophysiology of mood disorders.⁷⁸ For example, in healthy males, pregnanolone administration resulted in a sevenfold rise in allopregnanolone that was related to reduced amygdala and insula responses to emotional stimuli, as compared with placebo.⁷⁹ In addition, pregnanolone decreased connectivity between the amygdala and important nodes of the default mode network (precuneus, dorsomedial prefrontal cortex and hippocampus), which related to a reduction in self-reported negative affect.⁸⁰ A study of healthy female participants showed that administration of progesterone resulting in luteal phase levels of allopregnanolone led to increased amygdala responses to emotional stimuli,³⁷ while higher allopregnanolone levels in the same individuals related to reduced responses.⁸¹ These equivocal findings may be due to the studies' small sample sizes, but also to either the specific dosage of

the substance administered or the sex of the participants. The response most likely also relates to the complex dose-dependent effect of allopregnanolone, where higher doses are known to induce anxiolysis and moderate doses are linked to paradoxical mood effects in susceptible persons.³² No neuroimaging studies have examined the effect of a GAMSA or a NAM of the GABA_A receptor on brain function. However, in naturally cycling women without premenstrual symptoms, increased peripheral levels of isoallopregnanolone relative to allopregnanolone have been related to lower amygdala activity in response to emotional stimuli during the luteal phase of the menstrual cycle.⁸²

Effects of neurosteroids in PMDD

In women with PMDD, premenstrual mood improves when serum levels of allopregnanolone are decreased, either by inhibition of ovarian progesterone/allopregnanolone production or hampering of progesterone metabolism to allopregnanolone using a 5 α reductase inhibitor.^{83,84} Like other GABA_A receptor agonists – for example, benzodiazepines and barbiturates – allopregnanolone may induce tolerance and this has been demonstrated in animal studies.⁸⁵ In the SEV model, women with PMDD were shown to have an altered sensitivity to intravenous injections of allopregnanolone in comparison with healthy controls. PMDD women were more sensitive during the luteal phase as opposed to during the follicular phase, whereas the opposite was seen in healthy controls. The conclusion from these results was that women with PMDD might not be able to develop a physiological tolerance to allopregnanolone during the luteal phase.⁸⁶

In a study of postmenopausal women sequentially treated with oestradiol and progesterone, prior PMDD was a risk factor for development of negative mood depending on the level of metabolism to allopregnanolone.^{36,87} However, not only is allopregnanolone of importance but also oestradiol concentrations can drive negative mood reactions. When anovulatory women with PMDD were given a combination of oestradiol and progesterone, a higher dose of the former caused a more pronounced negative mood.¹⁷

Direct allopregnanolone administration has never been evaluated in women with PMDD using neuroimaging methods. However, emotion processing-related fMRI studies suggest effects of PMDD in key regions of the limbic system, including the amygdala, anterior cingulate cortex and insula, as well as the prefrontal cortex across the menstrual cycle during which allopregnanolone levels are fluctuating (see Fig. 3 and Dubol et al).⁸⁸ Reductions in grey matter volume have also been reported in the luteal phase in PMDD.⁸⁸ However, recent studies have shown that widespread reductions of cortical thickness in PMDD seem to be independent of menstrual cycle phase.⁸⁹ Structural brain differences may thus reflect an underlying vulnerability to developing PMDD symptoms and are relatively stable in the context of fluctuating steroid levels. However, functional measures of brain activity have previously been associated with circulating steroids: for instance, activity of the amygdala during the luteal phase has been linked to progesterone and progesterone-derived neurosteroid levels in women with PMDD.^{82,90} Aberrant activation of the amygdala is commonly observed in mood and anxiety disorders.⁷⁸ Interestingly, increased amygdala activity during the luteal phase has been related to lower transcriptional expression of the delta subunit of the GABA_A receptor in peripheral immune cells in women with PMDD.⁹¹ Delta-containing GABA_A receptors are exclusively extrasynaptic and mediate tonic inhibition, and are thus considered to be an important determinant of baseline neuronal excitability.⁹² Furthermore, the delta subunit is thought to endow the GABA_A receptor with a heightened sensitivity to




Fig. 3 Functional and structural brain differences in women with premenstrual dysphoric disorder (PMDD). Regions in light blue correspond to higher activity reported in control subjects compared with women with PMDD. Regions shown in medium blue correspond to higher activity or grey matter volume reported in women with PMDD compared with control subjects. Regions shown in dark blue correspond to mixed patterns of functional differences reported between women with PMDD and control subjects. ACC, anterior cingulate cortex; Amg, amygdala; Cb VI, cerebellum VI lobule; CS, control subjects; fMRI, functional MRI; IFG, inferior frontal gyrus; IPL, inferior parietal lobule; LL, late luteal phase; MeFG, medial frontal gyrus; MF, mid-follicular phase; MFG, middle frontal gyrus; PMDD, premenstrual dysphoric disorder; PoG, postcentral gyrus; Post Ins, posterior insula; PrG, precentral gyrus; SFG, superior frontal gyrus; sMRI, structural MRI. Reprinted with permission from Dubol et al.⁸⁸

allopregnanolone, and brain expression of this receptor is linked to reproductive status in rodents.^{49,93–96} Deficits in delta-GABA_A receptor expression are linked to affective disturbances in animal models.^{93,95} Whether delta-containing GABA_A receptors are differentially expressed at the regional brain level in women with PMDD remains to be determined. Nonetheless, aberrant regulation of delta-containing GABA_A receptors represents an interesting hypothesis explaining the differential behavioural and pharmacodynamic responses observed in these women in response to fluctuating allopregnanolone levels.

Like allopregnanolone, its isomer pregnanolone is a PAM of the GABA_A receptor but its effect is less studied in PMDD. However, a recent study has revealed that pregnanolone levels in the luteal phase are affected by treatment with a selective serotonin reuptake inhibitor (SSRI), a common treatment for PMDD.⁹⁷ In women with PMDD, SSRI treatment has been shown to normalise sensibility to pregnanolone in an experimental SEV model.⁹⁸ SSRIs appear to have steroidogenic effects, even at low doses, and to increase the synthesis of allopregnanolone.⁹⁹

Pregnenolone sulphate is a NAM of the GABA_A receptor but also a PAM of the NMDA receptor. Studies in PMDD women are scarce, but there are some indications that pregnenolone sulphate is also of importance regarding symptom severity in this group.¹⁰⁰

The role of oestradiol in PMDD pathophysiology

The ovaries are the main source of circulating oestradiol in women of fertile age, but variations in regional intracerebral distribution are also due to brain-derived 17 β -oestradiol from neurons and astrocytes.¹⁰¹ 17 β -oestradiol has a high affinity to the genomic receptors ER α and ER γ , which are abundant in the human brain. In addition to reproductive processes, both receptor types appear to

play a role in neuronal functioning and neurodegenerative diseases.¹⁰² In addition to genomic receptors, the membrane-bound ER α has been shown to promote the pre-ovulatory surge in luteinising hormone.¹⁰³ However, 17 β -oestradiol has also been shown to have a rapid and direct neuromodulatory effect that appears to be mediated by NMDA receptors.^{101,104} Contrary to the effect of PAMs, oestradiol is thus pro-excitatory, at least in areas such as the hippocampus.¹⁰⁵ In addition to reproduction and sexual behaviour, oestradiol appears to promote synaptic plasticity, cognitive function and neuroprotection.¹⁰¹ In women with premenstrual dysphoria, increased oestradiol levels have been shown to aggravate the detrimental effects of progesterone on mood when administered during the luteal phase, or in combined menopausal hormone therapy with synthetic progestins.^{106–108} However, fluctuations of oestradiol might be more harmful than the actual circulating levels.¹⁰⁹ Symptoms of mental disorders in women usually fluctuate over the menstrual cycle and, in an exploratory study a relationship between perimenstrual oestradiol levels and suicide ideations, could be confirmed.¹¹⁰ Moreover, treatment with oestradiol, to prevent the rapid decline of circulating levels perimenstrually, reduced suicidal ideations and improved cognitive function.¹¹⁰ Furthermore, an increased risk of developing PMDD has been found in women with oestrogen receptor alpha mutations.¹¹¹ However, very little is known about the mechanisms underlying oestradiol effects on the brain. Brain imaging studies have revealed oestradiol-mediated effects on brain morphology during the menstrual cycle in healthy women.¹¹² In particular, the plasticity of brain regions important for cognitive functions, such as the CA1 area of the hippocampus, appeared to be affected by fluctuations in ovarian steroids.¹¹² Very few neuroimaging studies have investigated associations between oestradiol levels and brain functional measures in PMDD populations. One small fMRI study ($N = 28$) showed a relationship between medial prefrontal cortex activation and oestradiol levels during the

luteal phase in women with PMDD during emotion processing.¹¹³ However, subsequent studies have not replicated this finding.^{82,91}

Treatment for PMDD

First-line treatment for PMDD today is an SSRI.¹¹⁴ Although efficacy is equal or slightly better for continuous as compared with intermittent treatment, the latter regimen reduces problems with side-effects and mitigates withdrawal symptoms.^{115,116} Overall, the effect on mood symptoms is generally good although side-effects are common and compliance usually low.^{117,118} Current recommendations also include complimentary non-pharmacological treatments and, for the less burdensome premenstrual syndrome (PMS), cognitive behavioural therapy is first-line treatment according to the American College of Obstetricians and Gynecologists.¹¹⁴

Especially for women requesting contraception, combined oral contraceptives (COCs) could be a good alternative, and combinations of a low dose of ethinyl oestradiol and drospirenone have proved efficient in ameliorating PMDD symptoms.^{114,119} A more recent meta-analysis concluded that all types of COC are equally efficient when treating PMDD and PMS, but the effect on premenstrual depression was weak overall.¹²⁰

In addition, the effectiveness of non-contraceptive oestradiol preparations for treatment of PMS symptoms has been investigated in a meta-analysis.¹²¹ The purpose of this study was to inhibit ovulation and exert a moderate effect on mood symptoms, but no effect on quality of life was found. Overall, the studies were of low quality and adverse effects, due to the progestogen component that was added to protect the endometrium from hyperplasia, were common.¹²¹ Today, oestradiol is not recommended for treatment of premenstrual mood symptoms.¹¹⁴

Since ovulation is a prerequisite for PMDD, treatment with a GnRH analogue is usually effective and an option when no other treatment works.^{114,122} The problem is that add-back must be given to protect the woman from osteoporosis and other negative effects of oestrogen deprivation, with the risk of triggering negative mood.¹⁷ Interestingly, in a small observational study of 12 women with PMDD who responded to GnRH treatment, PMDD symptoms recurred initially when oestradiol and progestogen were added but, when steroid levels were stable for the remaining 2–3 months of treatment, PMDD symptoms declined.¹⁰⁹

Ulipristal is a selective progesterone receptor modulator that has shown promising effects on PMDD symptoms in a placebo-controlled, randomised trial.¹²³ Due to reports of liver damage, ulipristal has been taken off the market in many countries but nevertheless the study constituted a proof of concept.

Isoallopregnanolone has been tested in two randomised, placebo-controlled trials as a treatment modality for PMDD.^{124,125} Active drug and placebo were administered repeatedly as subcutaneous injections during the luteal phase, and treatment was double-blinded. A significant reduction of negative mood was detected on a validated PMDD scale during 9 days in the luteal phase, and no severe side-effects were reported.^{124,125} Moreover, the effect size was similar to that obtained in other treatment studies with SSRIs or COCs in women with PMDD and using the same outcome measures.^{126–128}

Future directions

In conclusion, women with PMDD react differently when exposed to neurosteroids, such as the progesterone metabolite allopregnanolone, a positive allosteric modulator of the GABA_A receptor. This has been shown in fMRI studies, as well as clinically in anovulatory women

given a cyclical treatment with bioidentical oestradiol and progesterone that mimic the menstrual cycle. A potential target for future drug development is the GABA_A receptor itself, and/or drugs that modulate the effect of allosteric modulators – for example, allopregnanolone. The future drug development suggested above is costly and will take many years (from animal experiments to human experimentation and clinical drug trials). Nevertheless, improvement of PMDD treatment is possible based on current knowledge. Suppressed ovulation is successful, providing that levels of oestrogen and progestogen can be balanced and kept stable. Clinical trials with larger populations and longer follow-up could give useful insight into how to tailor these treatments. Selective modulators of steroid receptors and combinations of GnRH antagonists and add-back hormones are available for other indications, and could be tested in clinical trials for PMDD. The latter could be more feasible for patients than injectable GnRH analogues with separate add-back hormones, because this combined compound is administered orally as one tablet per day. Also, initial flare-up effects, which are common with GnRH analogues, are avoided.

Marie Bixo , Department of Clinical Sciences, Obstetrics and Gynaecology, Umeå University, Sweden; **Louise Stiernman**, Department of Clinical Sciences, Obstetrics and Gynaecology, Umeå University, Sweden; **Torbjörn Bäckström**, Department of Clinical Sciences, Obstetrics and Gynaecology, Umeå University, Sweden

Correspondence: Marie Bixo. Email: marie.bixo@umu.se

First received 29 Oct 2024, final revision 17 Mar 2025, accepted 25 Mar 2025

Data availability statement

This narrative review is mainly based on previous research from which data are not available to the authors. Data from studies by the authors are available on request.

Author contributions

M.B., L.S. and T.B. contributed to the conception, drafting and final approval of this work. The authors are accountable for all aspects of the work.

Funding

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

Declaration of interest

T.B. has shares in Umeçrine Cognition. M.B. and L.S. have no conflicts of interest.

References

- O'Brien PM, Backstrom T, Brown C, Dennerstein L, Endicott J, Epperson CN, et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMDD Montreal consensus. *Arch Womens Ment Health* 2011; **14**: 13–21.
- Halbreich U, Borenstein J, Pearlstein T, Kahn LS. The prevalence, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). *Psychoneuroendocrinology* 2003; **28**: 1–23.
- Reilly TJ, Patel S, Unachukwu IC, Knox CL, Wilson CA, Craig MC, et al. The prevalence of premenstrual dysphoric disorder: systematic review and meta-analysis. *J Affect Disord* 2024; **349**: 534–40.
- Dennerstein L, Lehert P, Backstrom TC, Heinemann K. The effect of premenstrual symptoms on activities of daily life. *Fertil Steril* 2010; **94**: 1059–64.
- Wikman A, Sacher J, Bixo M, Hirschberg AL, Kopp Kallner H, Epperson CN, et al. Prevalence and correlates of current suicidal ideation in women with premenstrual dysphoric disorder. *BMC Womens Health* 2022; **22**: 35.
- American Psychiatric Association (APA). *The Diagnostic and Statistical Manual of Mental Disorders (DSM-5)*. APA, 2013.

- 7 Kaiser G, Janda C, Kleinstaubner M, Weise C. Clusters of premenstrual symptoms in women with PMDD: appearance, stability and association with impairment. *J Psychosom Res* 2018; **115**: 38–43.
- 8 Pearlstein T, Yonkers KA, Fayyad R, Gillespie JA. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. *J Affect Disord* 2005; **85**: 275–82.
- 9 Dennerstein L, Leher P, Backstrom TC, Heinemann K. Premenstrual symptoms – severity, duration and typology: an international cross-sectional study. *Menopause Int* 2009; **15**: 120–6.
- 10 Kim DR, Gyulai L, Freeman EW, Morrison MF, Baldassano C, Dube B. Premenstrual dysphoric disorder and psychiatric co-morbidity. *Arch Womens Ment Health* 2004; **7**: 37–47.
- 11 Pilver CE, Levy BR, Libby DJ, Desai RA. Posttraumatic stress disorder and trauma characteristics are correlates of premenstrual dysphoric disorder. *Arch Womens Ment Health* 2011; **14**: 383–93.
- 12 Yang Q, Thornore-Heah D, Hauksdottir A, Aspelund T, Jakobsdottir J, Halldorsdottir T, et al. Association between adverse childhood experiences and premenstrual disorders: a cross-sectional analysis of 11,973 women. *BMC Med* 2022; **20**: 60.
- 13 Backstrom T, Bixo M, Johansson M, Nyberg S, Ossewaarde L, Ragagnin G, et al. Allopregnanolone and mood disorders. *Prog Neurobiol* 2014; **113**: 88–94.
- 14 Sundstrom-Poromaa I, Comasco E, Sumner R. Friend or foe? *Front Neuroendocrinol* 2020; **59**: 100856.
- 15 Hammarback S, Backstrom T. Induced anovulation as treatment of premenstrual tension syndrome. A double-blind cross-over study with GnRH-agonist versus placebo. *Acta Obstet Gynecol Scand* 1988; **67**: 159–66.
- 16 Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. *N Engl J Med* 1998; **338**: 209–16.
- 17 Segebladh B, Borgstrom A, Nyberg S, Bixo M, Sundstrom-Poromaa I. Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. *Am J Obstet Gynecol* 2009; **201**: 139 e1–8.
- 18 Bjorn I, Bixo M, Nojd KS, Nyberg S, Backstrom T. Negative mood changes during hormone replacement therapy: a comparison between two progestogens. *Am J Obstet Gynecol* 2000; **183**: 1419–26.
- 19 Bencker C, Gschwandtner L, Nayman S, Griksiene R, Nguyen B, Nater UM, et al. Progestagens and progesterone receptor modulation: effects on the brain, mood, stress, and cognition in females. *Front Neuroendocrinol* 2024; **76**: 101160.
- 20 Chan AF, Mortola JF, Wood SH, Yen SS. Persistence of premenstrual syndrome during low-dose administration of the progesterone antagonist RU 486. *Obstet Gynecol* 1994; **84**: 1001–5.
- 21 Wang M, Backstrom T, Sundstrom I, Wahlstrom G, Olsson T, Zhu D, et al. Neuroactive steroids and central nervous system disorders. *Int Rev Neurobiol* 2001; **46**: 421–59.
- 22 Paul SM, Purdy RH. Neuroactive steroids. *FASEB J* 1992; **6**: 2311–22.
- 23 Backstrom T, Gee KW, Lan N, Sorensen M, Wahlstrom G. Steroids in relation to epilepsy and anaesthesia. *Ciba Found Symp* 1990; **153**: 225–30.
- 24 Beauchamp MH, Ormerod BK, Jhamandas K, Boegman RJ, Beninger RJ. Neurosteroids and reward: allopregnanolone produces a conditioned place aversion in rats. *Pharmacol Biochem Behav* 2000; **67**: 29–35.
- 25 Fish EW, Faccidomo S, DeBold JF, Miczek KA. Alcohol, allopregnanolone and aggression in mice. *Psychopharmacology (Berl)* 2001; **153**: 473–83.
- 26 Hantsoo L, Sajid H, Murphy L, Buchert B, Barone J, Raja S, et al. Patient experiences of health care providers in premenstrual dysphoric disorder: examining the role of provider specialty. *J Womens Health (Larchmt)* 2022; **31**: 100–9.
- 27 Kurthen M, Linke DB, Reuter BM, Hufnagel A, Elger CE. Severe negative emotional reactions in intracarotid sodium amytal procedures: further evidence for hemispheric asymmetries? *Cortex* 1991; **27**: 333–7.
- 28 Masia SL, Perrine K, Westbrook L, Alper K, Devinsky O. Emotional outbursts and post-traumatic stress disorder during intracarotid amobarbital procedure. *Neurology* 2000; **54**: 1691–3.
- 29 Yoshimura H, Ogawa N. Acute and chronic effects of psychotropic drugs on maternal aggression in mice. *Psychopharmacology (Berl)* 1989; **97**: 339–42.
- 30 Miczek KA, DeBold JF, van Erp AM. GABA_A-benzodiazepine receptor complex, and aggression. *Recent Dev Alcohol* 1997; **13**: 139–71.
- 31 Wenzel RR, Bartel T, Eggebrecht H, Philipp T, Erbel R. Central-nervous side effects of midazolam during transesophageal echocardiography. *J Am Soc Echocardiogr* 2002; **15**: 1297–300.
- 32 Backstrom T, Haage D, Lofgren M, Johansson IM, Stromberg J, Nyberg S, et al. Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons. *Neuroscience* 2011; **191**: 46–54.
- 33 Ben-Porath DD, Taylor SP. The effects of diazepam (valium) and aggressive disposition on human aggression: an experimental investigation. *Addict Behav* 2002; **27**: 167–77.
- 34 Matsumoto T, Kaneko A, Fujiki T, Kusakabe Y, Nakayama E, Tanaka A, et al. Impact of adding pethidine on disinhibition during bronchoscopy with midazolam: a propensity score matching analysis. *Respir Investig* 2023; **61**: 409–17.
- 35 Tschudin S, Berteau PC, Zemp E. Prevalence and predictors of premenstrual syndrome and premenstrual dysphoric disorder in a population-based sample. *Arch Womens Ment Health* 2010; **13**: 485–94.
- 36 Andreen L, Sundstrom-Poromaa I, Bixo M, Nyberg S, Backstrom T. Allopregnanolone concentration and mood – a bimodal association in postmenopausal women treated with oral progesterone. *Psychopharmacology (Berl)* 2006; **187**: 209–21.
- 37 van Wingen GA, van Broekhoven F, Verkes RJ, Petersson KM, Backstrom T, Buitelaar JK, et al. Progesterone selectively increases amygdala reactivity in women. *Mol Psychiatry* 2008; **13**: 325–33.
- 38 Paulus MP, Feinstein JS, Castillo G, Simmons AN, Stein MB. Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. *Arch Gen Psychiatry* 2005; **62**: 282–8.
- 39 Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. *Science* 1986; **232**: 1004–7.
- 40 Olsen RW, Sieghart W. GABA A receptors: subtypes provide diversity of function and pharmacology. *Neuropharmacology* 2009; **56**: 141–8.
- 41 Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. *Nat Rev Neurosci* 2005; **6**: 215–29.
- 42 Pirker S, Schwarzer C, Wieselthaler A, Sieghart W, Sperk G. GABA(A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. *Neuroscience* 2000; **101**: 815–50.
- 43 Belelli D, Lambert JJ. Neurosteroids: endogenous regulators of the GABA(A) receptor. *Nat Rev Neurosci* 2005; **6**: 565–75.
- 44 Uusi-Oukari M, Korpi ER. Regulation of GABA(A) receptor subunit expression by pharmacological agents. *Pharmacol Rev* 2010; **62**: 97–135.
- 45 Locci A, Pinna G. Neurosteroid biosynthesis down-regulation and changes in GABA_A receptor subunit composition: a biomarker axis in stress-induced cognitive and emotional impairment. *Br J Pharmacol* 2017; **174**: 3226–41.
- 46 Bixo M, Andersson A, Winblad B, Purdy RH. 5 α -pregnan-3,20-dione and 3 α -hydroxy-5 α -pregnan-20-one in specific regions of the human female brain in different endocrine states. *Brain Res* 1997; **764**: 173–8.
- 47 Bengtsson SKS, Backstrom T, Brinton R, Irwin RW, Johansson M, Sjostedt J, et al. GABA-A receptor modulating steroids in acute and chronic stress; relevance for cognition and dementia? *Neurobiol Stress* 2020; **12**: 100206.
- 48 Reddy DS, Estes WA. Clinical potential of neurosteroids for CNS disorders. *Trends Pharmacol Sci* 2016; **37**: 543–61.
- 49 Belelli D, Casula A, Ling A, Lambert JJ. The influence of subunit composition on the interaction of neurosteroids with GABA(A) receptors. *Neuropharmacology* 2002; **43**: 651–61.
- 50 Timby E, Balgord M, Nyberg S, Spigset O, Andersson A, Porankiewicz-Asplund J, et al. Pharmacokinetic and behavioral effects of allopregnanolone in healthy women. *Psychopharmacology (Berl)* 2006; **186**: 414–24.
- 51 van Broekhoven F, Backstrom T, van Luitelaar G, Buitelaar JK, Smits P, Verkes RJ. Effects of allopregnanolone on sedation in men, and in women on oral contraceptives. *Psychoneuroendocrinology* 2007; **32**: 555–64.
- 52 Frye CA. The neurosteroid 3 α , 5 α -THP has antiseizure and possible neuroprotective effects in an animal model of epilepsy. *Brain Res* 1995; **696**: 113–20.
- 53 Norberg L, Backstrom T, Wahlstrom G. Anaesthetic effects of pregnanolone in combination with allopregnanolone, thiopental, hexobarbital and flurazepam: an EEG study in the rat. *Br J Anaesth* 1999; **82**: 731–7.
- 54 Akwa Y, Purdy RH, Koob GF, Britton KT. The amygdala mediates the anxiolytic-like effect of the neurosteroid allopregnanolone in rat. *Behav Brain Res* 1999; **106**: 119–25.
- 55 Yawno T, Yan EB, Hirst JJ, Walker DW. Neuroactive steroids induce changes in fetal sheep behavior during normoxic and asphyxial states. *Stress* 2011; **14**: 13–22.
- 56 Brunton PJ, Russell JA, Hirst JJ. Allopregnanolone in the brain: protecting pregnancy and birth outcomes. *Prog Neurobiol* 2014; **113**: 106–36.
- 57 Guo K, Mao M, Zhang S, Xu S, Zhao L, Wang X, et al. Research trends and hot spots of allopregnanolone research in the last 20 years: a bibliometric analysis. *Drug Des Devel Ther* 2023; **17**: 3397–408.
- 58 Epperson CN, Rubinow DR, Meltzer-Brody S, Deligiannidis KM, Riesenberger R, Krystal AD, et al. Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: pooled analyses from 3

- double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program. *J Affect Disord* 2023; **320**: 353–9.
- 59 Barnes KN, Vogl CM, Nelson LA. Zuranolone: the first FDA-approved oral treatment option for postpartum depression. *Ann Pharmacother* 2024; **58**: 728–34.
 - 60 Zhu D, Wang MD, Backstrom T, Wahlstrom G. Evaluation and comparison of the pharmacokinetic and pharmacodynamic properties of allopregnanolone and pregnanolone at induction of anaesthesia in the male rat. *Br J Anaesth* 2001; **86**: 403–12.
 - 61 Rahman M, Lindblad C, Johansson IM, Backstrom T, Wang MD. Neurosteroid modulation of recombinant rat $\alpha 5\beta 2\gamma 2L$ and $\alpha 1\beta 2\gamma 2L$ GABA(A) receptors in *Xenopus* oocyte. *Eur J Pharmacol* 2006; **547**: 37–44.
 - 62 Lundgren P, Stromberg J, Backstrom T, Wang M. Allopregnanolone-stimulated GABA-mediated chloride ion flux is inhibited by 3 β -hydroxy-5 α -pregnan-20-one (isoallopregnanolone). *Brain Res* 2003; **982**: 45–53.
 - 63 Backstrom T, Wahlstrom G, Wahlstrom K, Zhu D, Wang MD. Isoallopregnanolone; an antagonist to the anaesthetic effect of allopregnanolone in male rats. *Eur J Pharmacol* 2005; **512**: 15–21.
 - 64 Wang M, He Y, Eisenman LN, Fields C, Zeng CM, Mathews J, et al. 3 β -hydroxypregnan-20-one is a pregnanolone sulfate-like GABA(A) receptor antagonist. *J Neurosci* 2002; **22**: 3366–75.
 - 65 Hill M, Cibula D, Havlikova H, Kancheva L, Fait T, Kancheva R, et al. Circulating levels of pregnanolone isomers during the third trimester of human pregnancy. *J Steroid Biochem Mol Biol* 2007; **105**: 166–75.
 - 66 Corpechot C, Young J, Calvel M, Wehrey C, Veltz JN, Touyer G, et al. Neurosteroids: 3 α -hydroxy-5 α -pregnan-20-one and its precursors in the brain, plasma, and steroidogenic glands of male and female rats. *Endocrinology* 1993; **133**: 1003–9.
 - 67 Havlikova H, Hill M, Kancheva L, Vrbikova J, Pouzar V, Cerny I, et al. Serum profiles of free and conjugated neuroactive pregnanolone isomers in nonpregnant women of fertile age. *J Clin Endocrinol Metab* 2006; **91**: 3092–9.
 - 68 Kancheva R, Hill M, Cibula D, Vcelakova H, Kancheva L, Vrbikova J, et al. Relationships of circulating pregnanolone isomers and their polar conjugates to the status of sex, menstrual cycle, and pregnancy. *J Endocrinol* 2007; **195**: 67–78.
 - 69 Belyaeva OV, Chetyrkin SV, Clark AL, Kostereva NV, SantaCruz KS, Chronwall BM, et al. Role of microsomal retinol/sterol dehydrogenase-like short-chain dehydrogenases/reductases in the oxidation and epimerization of 3 α -hydroxysteroids in human tissues. *Endocrinology* 2007; **148**: 2148–56.
 - 70 Huang XF, Luu-The V. Molecular characterization of a first human 3(α -> β)-hydroxysteroid epimerase. *J Biol Chem* 2000; **275**: 29452–7.
 - 71 Gee KW, Chang WC, Brinton RE, McEwen BS. GABA-dependent modulation of the Cl⁻ ionophore by steroids in rat brain. *Eur J Pharmacol* 1987; **136**: 419–23.
 - 72 Lambert JJ, Belelli D, Hill-Venning C, Peters JA. Neurosteroids and GABA_A receptor function. *Trends Pharmacol Sci* 1995; **16**: 295–303.
 - 73 Stromberg J, Haage D, Taube M, Backstrom T, Lundgren P. Neurosteroid modulation of allopregnanolone and GABA effect on the GABA-A receptor. *Neuroscience* 2006; **143**: 73–81.
 - 74 Haage D, Backstrom T, Johansson S. Interaction between allopregnanolone and pregnanolone sulfate in modulating GABA-mediated synaptic currents in neurons from the rat medial preoptic nucleus. *Brain Res* 2005; **1033**: 58–67.
 - 75 Seljeset S, Liebowitz S, Bright DP, Smart TG. Pre- and postsynaptic modulation of hippocampal inhibitory synaptic transmission by pregnanolone sulphate. *Neuropharmacology* 2023; **233**: 109530.
 - 76 de Visser SJ, van der Post JP, de Waal PP, Cornet F, Cohen AF, van Gerven JM. Biomarkers for the effects of benzodiazepines in healthy volunteers. *Br J Clin Pharmacol* 2003; **55**: 39–50.
 - 77 Bengtsson SK, Nyberg S, Hedstrom H, Zingmark E, Jonsson B, Backstrom T, et al. Isoallopregnanolone antagonize allopregnanolone-induced effects on saccadic eye velocity and self-reported sedation in humans. *Psychoneuroendocrinology* 2015; **52**: 22–31.
 - 78 Menon V. Large-scale brain networks and psychopathology: a unifying triple network model. *Trends Cogn Sci* 2011; **15**: 483–506.
 - 79 Sripada RK, Marx CE, King AP, Rampton JC, Ho SS, Liberzon I. Allopregnanolone elevations following pregnanolone administration are associated with enhanced activation of emotion regulation neurocircuits. *Biol Psychiatry* 2013; **73**: 1045–53.
 - 80 Sripada RK, Welsh RC, Marx CE, Liberzon I. The neurosteroids allopregnanolone and dehydroepiandrosterone modulate resting-state amygdala connectivity. *Hum Brain Mapp* 2014; **35**: 3249–61.
 - 81 van Wingen G, van Broekhoven F, Verkes RJ, Petersson KM, Backstrom T, Buitelaar J, et al. How progesterone impairs memory for biologically salient stimuli in healthy young women. *J Neurosci* 2007; **27**: 11416–23.
 - 82 Stiernman L, Dubol M, Comasco E, Sundstrom-Poromaa I, Boraxbekk CJ, Johansson M, et al. Emotion-induced brain activation across the menstrual cycle in individuals with premenstrual dysphoric disorder and associations to serum levels of progesterone-derived neurosteroids. *Transl Psychiatry* 2023; **13**: 124.
 - 83 Martinez PE, Rubinow DR, Nieman LK, Koziol DE, Morrow AL, Schiller CE, et al. 5 α -reductase inhibition prevents the luteal phase increase in plasma allopregnanolone levels and mitigates symptoms in women with premenstrual dysphoric disorder. *Neuropsychopharmacology* 2016; **41**: 1093–102.
 - 84 Nyberg S, Backstrom T, Zingmark E, Purdy RH, Poromaa IS. Allopregnanolone decrease with symptom improvement during placebo and gonadotropin-releasing hormone agonist treatment in women with severe premenstrual syndrome. *Gynecol Endocrinol* 2007; **23**: 257–66.
 - 85 Turkmen S, Backstrom T, Wahlstrom G, Andreen L, Johansson IM. Tolerance to allopregnanolone with focus on the GABA-A receptor. *Br J Pharmacol* 2011; **162**: 311–27.
 - 86 Timby E, Backstrom T, Nyberg S, Stenlund H, Wihlbäck AC, Bixo M. Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls—a pilot study. *Psychopharmacology (Berl)* 2016; **233**: 2109–17.
 - 87 Andreen L, Nyberg S, Turkmen S, van Wingen G, Fernandez G, Backstrom T. Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABA_A modulators. *Psychoneuroendocrinology* 2009; **34**: 1121–32.
 - 88 Dubol M, Epperson CN, Lanzemberger R, Sundstrom-Poromaa I, Comasco E. Neuroimaging premenstrual dysphoric disorder: a systematic and critical review. *Front Neuroendocrinol* 2020; **57**: 100838.
 - 89 Dubol M, Stiernman L, Sundstrom-Poromaa I, Bixo M, Comasco E. Cortical morphology variations during the menstrual cycle in individuals with and without premenstrual dysphoric disorder. *J Affect Disord* 2024; **355**: 470–7.
 - 90 Gingnell M, Morell A, Bannbers E, Wikstrom J, Sundstrom Poromaa I. Menstrual cycle effects on amygdala reactivity to emotional stimulation in premenstrual dysphoric disorder. *Horm Behav* 2012; **62**: 400–6.
 - 91 Stiernman L. *Premenstrual Dysphoric Disorder. Brain Structure and Function, GABA_A-active Steroids, and GABA_A-Receptor Plasticity*. Umeå University, 2024.
 - 92 Zheleznova NN, Sedelnikova A, Weiss DS. Function and modulation of delta-containing GABA(A) receptors. *Psychoneuroendocrinology* 2009; **34** (Suppl 1): S67–73.
 - 93 Maguire JL, Stell BM, Rafizadeh M, Mody I. Ovarian cycle-linked changes in GABA(A) receptors mediating tonic inhibition alter seizure susceptibility and anxiety. *Nat Neurosci* 2005; **8**: 797–804.
 - 94 Maguire J, Mody I. Neurosteroid synthesis-mediated regulation of GABA(A) receptors: relevance to the ovarian cycle and stress. *J Neurosci* 2007; **27**: 2155–62.
 - 95 Maguire J, Mody I. GABA(A)_R plasticity during pregnancy: relevance to postpartum depression. *Neuron* 2008; **59**: 207–13.
 - 96 Maguire J, Ferando I, Simonsen C, Mody I. Excitability changes related to GABA_A receptor plasticity during pregnancy. *J Neurosci* 2009; **29**: 9592–601.
 - 97 Miller KN, Standeven L, Morrow AL, Payne JL, Epperson CN, Hantsoo L. GABAergic neuroactive steroid response to sertraline in premenstrual dysphoric disorder. *Psychoneuroendocrinology* 2024; **160**: 106684.
 - 98 Sundstrom I, Backstrom T. Citalopram increases pregnanolone sensitivity in patients with premenstrual syndrome: an open trial. *Psychoneuroendocrinology* 1998; **23**: 73–88.
 - 99 Pinna G. In a mouse model relevant for post-traumatic stress disorder, selective brain steroidogenic stimulants (SBSS) improve behavioral deficits by normalizing allopregnanolone biosynthesis. *Behav Pharmacol* 2010; **21**: 438–50.
 - 100 Wang M, Seippel L, Purdy RH, Backstrom T. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnanolone, pregnanolone sulfate, 5 α -pregnan-3,20-dione and 3 α -hydroxy-5 α -pregnan-20-one. *J Clin Endocrinol Metab* 1996; **81**: 1076–82.
 - 101 Brann DW, Lu Y, Wang J, Sareddy GR, Pratap UP, Zhang Q, et al. Brain-derived estrogen and neurological disorders. *Biology (Basel)* 2022; **11**: 1698.
 - 102 Sato K, Takayama KI, Saito Y, Inoue S. ERR α and ERR γ coordinate expression of genes associated with Alzheimer's disease, inhibiting DKK1 to suppress tau phosphorylation. *Proc Natl Acad Sci USA* 2024; **121**: e2406854121.
 - 103 Faure MC, Corona R, Roomans C, Lenfant F, Foidart JM, Cornil CA. Role of membrane estrogen receptor α on the positive feedback of estrogens on Kisspeptin and GnRH neurons. *eNeuro* 2024; **11**: ENEURO.0271-23.2024.
 - 104 Kow LM, Pfaff DW. Can distinctly different rapid estrogen actions share a common mechanistic step? *Horm Behav* 2018; **104**: 156–64.

- 105 Zadrán S, Qin Q, Bi X, Zadrán H, Kim Y, Foy MR et al. 17- β -Estradiol increases neuronal excitability through MAP kinase-induced calpain activation. *Proc Natl Acad Sci USA* 2009; **106**: 21936–41.
- 106 Seippel L, Backstrom T. Luteal-phase estradiol relates to symptom severity in patients with premenstrual syndrome. *J Clin Endocrinol Metab* 1998; **83**: 1988–92.
- 107 Dhar V, Murphy BE. Double-blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). *Psychoneuroendocrinology* 1990; **15**: 489–93.
- 108 Bjorn I, Sundstrom-Poromaa I, Bixo M, Nyberg S, Backstrom G, Backstrom T. Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy. *J Clin Endocrinol Metab* 2003; **88**: 2026–30.
- 109 Schmidt PJ, Martinez PE, Nieman LK, Koziol DE, Thompson KD, Schenkel L, et al. Premenstrual dysphoric disorder symptoms following ovarian suppression: triggered by change in ovarian steroid levels but not continuous stable levels. *Am J Psychiatry* 2017; **174**: 980–9.
- 110 Schmalenberger KM, Mulligan EM, Barone JC, Nagpal A, Divine MM, Maki PM, et al. Effects of acute estradiol administration on perimenstrual worsening of working memory, verbal fluency, and inhibition in patients with suicidal ideation: a randomized, crossover clinical trial. *Psychiatry Res* 2024; **342**: 116188.
- 111 Huo L, Straub RE, Roca C, Schmidt PJ, Shi K, Vakkalanka R, et al. Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene. *Biol Psychiatry* 2007; **62**: 925–33.
- 112 Zsido RG, Williams AN, Barth C, Serio B, Kurth L, Mildner T, et al. Ultra-high-field 7T MRI reveals changes in human medial temporal lobe volume in female adults during menstrual cycle. *Nat Ment Health* 2023; **1**: 761–71.
- 113 Gingnell M, Bannbers E, Wikstrom J, Fredrikson M, Sundstrom-Poromaa I. Premenstrual dysphoric disorder and prefrontal reactivity during anticipation of emotional stimuli. *Eur Neuropsychopharmacol* 2013; **23**: 1474–83.
- 114 ACOG. *Management of Premenstrual Disorders: ACOG Clinical Practice Guideline No. 7* 2013; 1516–33.
- 115 Reilly TJ, Wallman P, Clark I, Knox CL, Craig MC, Taylor D. Intermittent selective serotonin reuptake inhibitors for premenstrual syndromes: a systematic review and meta-analysis of randomised trials. *J Psychopharmacol* 2023; **37**: 261–7.
- 116 Jespersen C, Lauritsen MP, Frokjaer VG, Schroll JB. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder. *Cochrane Database Syst Rev* 2024; **8**: CD001396.
- 117 Marjoribanks J, Brown J, O'Brien PM, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. *Cochrane Database Syst Rev* 2013; **6**: CD001396.
- 118 Sundstrom-Poromaa I, Bixo M, Bjorn I, Nordh O. Compliance to antidepressant drug therapy for treatment of premenstrual syndrome. *J Psychosom Obstet Gynaecol* 2000; **21**: 205–11.
- 119 Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. *Cochrane Database Syst Rev* 2009; CD0065862.
- 120 de Wit AE, de Vries YA, de Boer MK, Scheper C, Fokkema A, Janssen CAH, et al. Efficacy of combined oral contraceptives for depressive symptoms and overall symptomatology in premenstrual syndrome: pairwise and network meta-analysis of randomized trials. *Am J Obstet Gynecol* 2021; **225**: 624–33.
- 121 Naheed B, Kuiper JH, Uthman OA. Non-contraceptive oestrogen-containing preparations for controlling symptoms of premenstrual syndrome. *Cochrane Database Syst Rev* 2017; **3**: CD010503.
- 122 Wyatt KM, Dimmock PW, Ismail KM, Jones PW. The effectiveness of GnRH-a with and without 'add-back' therapy in treating premenstrual syndrome: a meta analysis. *BJOG* 2004; **111**: 585–93.
- 123 Comasco E, Kopp Kallner H, Bixo M, Hirschberg AL, Nyback S, de Grauw H, et al. Ulipristal acetate for treatment of premenstrual dysphoric disorder: a proof-of-concept randomized controlled trial. *Am J Psychiatry* 2021; **178**: 256–65.
- 124 Bixo M, Ekberg K, Poromaa IS, Hirschberg AL, Jonasson AF, Andreen L, et al. Treatment of premenstrual dysphoric disorder with the GABA(A) receptor modulating steroid antagonist Sepranolone (UC1010) – a randomized controlled trial. *Psychoneuroendocrinology* 2017; **80**: 46–55.
- 125 Backstrom T, Ekberg K, Hirschberg AL, Bixo M, Epperson CN, Briggs P, et al. A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder. *Psychoneuroendocrinology* 2021; **133**: 105426.
- 126 Cohen LS, Miner C, Brown EW, Freeman E, Halbreich U, Sundell K, et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. *Obstet Gynecol* 2002; **100**: 435–44.
- 127 Halbreich U, Bergeron R, Yonkers KA, Freeman E, Stout AL, Cohen L. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. *Obstet Gynecol* 2002; **100**: 1219–29.
- 128 Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. *Obstet Gynecol* 2005; **106**: 492–501.
- 129 Draper CF, Duisters K, Weger B, Chakrabarti A, Harms AC, Brennan L, et al. Menstrual cycle rhythmicity: metabolic patterns in healthy women. *Sci Rep* 2018; **8**: 14568.